Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Angiotensin Ii. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 3/20 | 0.81 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.81 |
| ▸ | REN | P00797 | 3/20 | 0.64 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.62 |
| ▸ | ANPEP | P15144 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Ii SCHEMBL5052592 | 0.99 | AGTR2 (0.79) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL13232382 | 0.98 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL1189 | 0.98 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2566771 | 0.98 | AGTR2 (0.84) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL3465991 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL14990505 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL21267957 | 0.98 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL1585377 | 0.97 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL8898391 | 0.97 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP | |
| Angiotensin Ii SCHEMBL2183118 | 0.97 | AGTR2 (0.83) | AGTR2AGTR1RENLNPEPANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230059301-A1 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | NORRIS, ANDREW | 2023-02-23 | — | — | US | disclosed |
| US-20200399312-A1 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | NATIONAL INSTITUTE OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-24 | — | — | US | disclosed |
| US-10640535-B2 | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies | AGENUS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10119975-B2 | Methods and systems for cell state quantification | GINKGO BIOWORKS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20170074889-A1 | METHODS AND SYSTEMS FOR CELL STATE QUANTIFICATION | GINKGO BIOWORKS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-9506167-B2 | Methods and systems for cell state quantification | GINKGO BIOWORKS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-9279011-B2 | Phosphopeptides as melanoma vaccines | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150225456-A1 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group | 2015-08-13 | — | — | US | disclosed |
| EP-2854842-A2 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | Phosimmune Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013177593-A2 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | PHOSIMMUNE, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130029879-A1 | Methods and Systems for Cell State Quantification | GINKGO BIOWORKS (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120177669-A1 | PHOSPHOPEPTIDES AS MELANOMA VACCINES | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-07-12 | — | — | US | disclosed |
| WO-2010129537-A1 | PHOSPHOPEPTIDES AS MELANOMA VACCINES | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2008156752-A2 | VITREOUS BIOMARKERS AND RELATED DIAGNOSTICS AND THERAPEUTICS | THE NATIONAL RETINA INSTITUTE (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1551439-A2 | IMPROVED SYSTEMS AND METHODS FOR ANALYSIS OF PROTEIN POST-TRANSLATIONAL MODIFICATION | MDS Proteomics Inc. (CA) | 2005-07-13 | — | — | EP | disclosed |
| US-20040161795-A1 | Systems and methods for analysis of protein post-translational modification | MDS PROTEOMICS INC. (CA) | 2004-08-19 | — | — | US | disclosed |
| WO-2004011902-A2 | IMPROVED SYSTEMS AND METHODS FOR ANALYSIS OF PROTEIN POST-TRANSLATIONAL MODIFICATION | MDS PROTEOMICS INC. (CA) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399312-A1 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | MICA, HLA-DRB1, TAP1 | AGTR1 4072/4885AGTR2 4666/4885REN 4531/4885 |
| US-20150225456-A1 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | MICA, HLA-DRB1, TAP1 | AGTR1 4072/4885AGTR2 4666/4885REN 4531/4885 |
| US-10640535-B2 | Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies | MICA, HLA-DRB1, TAP1 | AGTR1 4072/4885AGTR2 4666/4885REN 4531/4885 |
| US-20230059301-A1 | IDENTIFICATION OF MHC CLASS I PHOSPHO-PEPTIDE ANTIGENS FROM BREAST CANCER UTILIZING SHLA TECHNOLOGY AND COMPLEMENTARY ENRICHMENT STRATEGIES | MICA, HLA-DRB1, TAP1 | AGTR1 4072/4885AGTR2 4666/4885REN 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.